Difference between revisions of "Cetuximab (Erbitux)"
Jump to navigation
Jump to search
m |
|||
| Line 19: | Line 19: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
* 2/12/2004: Initial FDA approval: | * 2/12/2004: Initial FDA approval: | ||
| − | + | ** "in combination with [[Irinotecan (Camptosar) | irinotecan]], is indicated for the treatment of [[Colon cancer | EGFR-expressing, metastatic colorectal carcinoma]] in patients who are refractory to [[Irinotecan (Camptosar)|irinotecan]]-based chemotherapy." | |
| − | + | ** "as a single agent is indicated for the treatment of [[Colon cancer | EGFR-expressing, metastatic colorectal carcinoma]] in patients who are intolerant to [[Irinotecan (Camptosar)|irinotecan]]-based chemotherapy." | |
| + | * 3/1/2006: FDA indication expanded: | ||
| + | ** "in combination with radiation therapy, is indicated for the treatment of locally or regionally advanced [[Head and neck cancer|squamous cell carcinoma of the head and neck]]." | ||
| + | ** "as a single agent is indicated for the treatment of patients with recurrent or metastatic [[Head and neck cancer|squamous cell carcinoma of the head and neck]] for whom prior [[:Category:Platinum agents|platinum]]-based therapy has failed." | ||
| + | * 11/7/2011: FDA indication changed: | ||
| + | ** "indicated for the treatment of recurrent locoregional disease or metastatic [[Head and neck cancer|squamous cell carcinoma of the head and neck]] in combination with [[:Category:Platinum agents|platinum]]-based therapy with [[Fluorouracil (5-FU)|5-FU]]." | ||
| + | ** "Retrospective subset analyses of metastatic or advanced colorectal cancer trials have not shown a treatment benefit for Erbitux in patients whose tumors had KRAS mutations in codon 12 or 13. Use of Erbitux is not recommended for the treatment of colorectal cancer with these mutations." | ||
| + | * 7/6/2012: FDA indication changed: | ||
| + | ** "indicated for the treatment of [[Colon cancer|K-Ras mutation-negative (wild-type), EGFR-expressing, metastatic colorectal cancer]] as determined by FDA-approved test, [[Colon_cancer#FOLFIRI_.26_Cetuximab|in combination with FOLFIRI]] for first-line treatment." | ||
| + | ** '''Limitation of Use''': Erbitux is not indicated for treatment of K-Ras mutation-positive colorectal cancer. | ||
==Also known as== | ==Also known as== | ||
Revision as of 02:30, 5 August 2017
General information
Class/mechanism: EGFR antagonist; monoclonal antibody that binds to the EGFR/HER1/c-ErbB-1 receptor tyrosine kinase, competitively inhibiting binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor-alpha. This results in inhibition of cell growth, induction of apoptosis, decreased matrix metalloproteinase, and decreased vascular endothelial growth factor production.[1][2][3]
Route: IV
Extravasation: neutral
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Cetuximab (Erbitux) patient drug information (Chemocare)[4]
- Brief patient counseling information can be found on page 8 of the package insert[1]
- Cetuximab (Erbitux) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 2/12/2004: Initial FDA approval:
- "in combination with irinotecan, is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are refractory to irinotecan-based chemotherapy."
- "as a single agent is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are intolerant to irinotecan-based chemotherapy."
- 3/1/2006: FDA indication expanded:
- "in combination with radiation therapy, is indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck."
- "as a single agent is indicated for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck for whom prior platinum-based therapy has failed."
- 11/7/2011: FDA indication changed:
- "indicated for the treatment of recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with 5-FU."
- "Retrospective subset analyses of metastatic or advanced colorectal cancer trials have not shown a treatment benefit for Erbitux in patients whose tumors had KRAS mutations in codon 12 or 13. Use of Erbitux is not recommended for the treatment of colorectal cancer with these mutations."
- 7/6/2012: FDA indication changed:
- "indicated for the treatment of K-Ras mutation-negative (wild-type), EGFR-expressing, metastatic colorectal cancer as determined by FDA-approved test, in combination with FOLFIRI for first-line treatment."
- Limitation of Use: Erbitux is not indicated for treatment of K-Ras mutation-positive colorectal cancer.
Also known as
C225